

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

Vyepti (eptinezumab-jjmr)

PHYSICIAN INFORMATION				PATIENT INFORMATION				
* Physician Name:			with the outcome	*Due to privacy regulations, we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this				
	Specialty: * DEA, NPI or TIN:		form are completed. *					
Office Contact Person:			* Patient Name:					
Office Phone:			* Cigna ID:			* Date of Birth:		
Office Fax:			* Patient Street Address:					
Office Street Address:		City:	State:		Zip:			
City:	State:	Zip:	Patient Phone:					
Urgency: ☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)								
Medication requested: ICD10: ☐ Vyepti 100mg/ml vial ☐ other (please specify):								
Directions for use:	Dosing and Quantity: Duration of therapy:							
Is this initial therapy or is the patient currently receiving Vyepti? Initial therapy Currently receiving Vyepti								
Facility and/or doctor dispensing and administering medication: Facility Name: State: Tax ID#: Address (City, State, Zip Code): Where will this drug be administered?								
☐ Patient's Home			Physician's Office					
☐ Hospital Outpatient ☐ Other (please specify):								
NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting. Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? ☐ Yes ☐ No (provide medical necessity rationale):								
Is the requested medication for the patient?	for which the preso	cription medi	cation may	y be neces	ssary for the life of			

What is your patient's diagnosis? Acute Treatment of Migraine Cluster Headache, Treatment or Prevention Migraine Headache Prevention Other (please specify):				
Clinical Information				
Besides the drug being requested, other calcitonin gene-related peptide (CGRP) inhibitors for migraine headache prevention include Aimovig (erenumab-aooe subcutaneous injection), Ajovy (fremanezumab-vfrm subcutaneous injection), Emgality (galcanezumab-gnisubcutaneous injection), and Qulipta (atogepant tablets). Which of the following best describes your patient's situation?				
The patient is NOT taking any other drug at this time, nor will they in the future. The requested drug is the only drug the patient				
is/will be using. The patient is currently on another drug, but this drug will be stopped and the requested drug will be started. The patient is currently on another drug, and the requested drug will be added. The patient may continue to take both drugs together.				
☐ The patient is currently on BOTH the requested drug AND another drug. ☐ other/unknown				
(if other/more than the requested drug) Please provide the rationale for concurrent use.				
Besides the drug being requested, other medications for preventive treatment of migraine include Nurtec ODT (rimegepant sulfate orally disintegrating tablet). Which of the following best describes your patient's situation?				
☐ The patient is NOT taking any other drug at this time, nor will they in the future. The requested drug is the only drug the patient is/will be using.				
The patient is currently on another drug, but this drug will be stopped and the requested drug will be started. The patient is currently on another drug, and the requested drug will be added. The patient may continue to take both drugs together.				
☐ The patient is currently on BOTH the requested drug AND another drug. ☐ other/unknown				
(if other/more than the requested drug) Please provide the rationale for concurrent use.				
PRIOR to initiating a migraine-preventative medication, how many days per month is/was your patient experiencing a migraine headache?				
☐ 3 or fewer ☐ 4 or more ☐ Unknown				
Is there documentation that your patient had failure, contraindication, or intolerance to any of the following? (Check all that apply):				
☐ Aimovig (erenumab-aooe) ☐ Ajovy (fremanezumab-vfrm) ☐ Emgality (galcanezumab-gnlm)				
For each alternative that your patient didn't try, please provide details why they can't try that alternative [including: contraindications according to the FDA label; warnings per the prescribing information (labeling); disease characteristic or clinical factor the patient has.				
Note: preferred drugs vary depending on the patient's health plan.				

Additional Pertinent Information : Please provide any additional pertinent clinical information, including: if the patient is currently on the requested drug (with dates of use) and how they have been receiving it (samples, out of pocket, etc).
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.
Prescriber Signature: Date:
Troothor eighten of
Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v071524

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005